Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Hyperphosphatemia In Chronic Kidney Disease Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Hyperphosphatemia In Chronic Kidney Disease Overview | 8 | 1 |
| Pipeline Products for Hyperphosphatemia In Chronic Kidney Disease Comparative Analysis | 9 | 1 |
| Hyperphosphatemia In Chronic Kidney Disease Therapeutics under Development by Companies | 10 | 1 |
| Hyperphosphatemia In Chronic Kidney Disease Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Hyperphosphatemia In Chronic Kidney Disease Pipeline Products Glance | 12 | 3 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Hyperphosphatemia In Chronic Kidney Disease Products under Development by Companies | 15 | 1 |
| Hyperphosphatemia In Chronic Kidney Disease Products under Investigation by Universities/Institutes | 16 | 1 |
| Hyperphosphatemia In Chronic Kidney Disease Companies Involved in Therapeutics Development | 17 | 9 |
| 3SBio Inc. | 17 | 1 |
| Ardelyx, Inc. | 18 | 1 |
| Daiichi Sankyo Company, Limited | 19 | 1 |
| Medice Arzneimittel Putter GmbH &Co. KG | 20 | 1 |
| OPKO Health, Inc. | 21 | 1 |
| Panion &Bf Biotech Inc | 22 | 1 |
| Shield Therapeutics Plc | 23 | 1 |
| Spectrum Pharmaceuticals, Inc. | 24 | 1 |
| Toray Industries, Inc. | 25 | 1 |
| Hyperphosphatemia In Chronic Kidney Disease Therapeutics Assessment | 26 | 8 |
| Assessment by Monotherapy Products | 26 | 1 |
| Assessment by Target | 27 | 2 |
| Assessment by Mechanism of Action | 29 | 2 |
| Assessment by Route of Administration | 31 | 1 |
| Assessment by Molecule Type | 32 | 2 |
| Drug Profiles | 34 | 25 |
| DS-2330 Drug Profile | 34 | 1 |
| fermagate Drug Profile | 35 | 1 |
| ferric citrate Drug Profile | 36 | 8 |
| JPH-101 Drug Profile | 44 | 1 |
| niacinamide Drug Profile | 45 | 1 |
| PDX-004 Drug Profile | 46 | 1 |
| PT-20 Drug Profile | 47 | 1 |
| RDX-002 Drug Profile | 48 | 1 |
| sevelamer carbonate Drug Profile | 49 | 1 |
| Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia In CKD Drug Profile | 50 | 1 |
| Small Molecules to Target Phosphate for Hyperphosphatemia Drug Profile | 51 | 1 |
| SPI-014 Drug Profile | 52 | 1 |
| tenapanor hydrochloride Drug Profile | 53 | 4 |
| TRK-390 Drug Profile | 57 | 1 |
| VS-501 Drug Profile | 58 | 1 |
| Hyperphosphatemia In Chronic Kidney Disease Dormant Projects | 59 | 1 |
| Hyperphosphatemia In Chronic Kidney Disease Discontinued Products | 60 | 1 |
| Hyperphosphatemia In Chronic Kidney Disease Product Development Milestones | 61 | 11 |
| Featured News &Press Releases | 61 | 1 |
| Sep 24, 2015: Keryx Receives European Approval for Fexeric (ferric citrate coordination complex) for the Treatment of Hyperphosphatemia in Adults With Chronic Kidney Disease | 61 | 1 |
| May 07, 2015: Phosphate Therapeutics announces positive results in the PEACH pivotal study of its novel phosphate binder (PT20) for the treatment of hyperphosphataemia | 62 | 1 |
| Mar 04, 2015: Keryx Biopharmaceuticals Announces Publication of Auryxia (ferric citrate) Analysis in Journal of the American Society of Nephrology | 62 | 1 |
| Feb 02, 2015: Ardelyx Reports Results from Phase 2b Clinical Trial Evaluating Tenapanor in Treating Hyperphosphatemia in Chronic Kidney Disease Patients on Hemodialysis | 63 | 1 |
| Jan 09, 2015: Keryx Biopharmaceuticals Turns to Veeva Commercial Cloud to Support First FDA-Approved Product Launch | 64 | 1 |
| Nov 17, 2014: Keryx Biopharmaceuticals Announces Trade Name Auryxia for Ferric Citrate | 65 | 1 |
| Nov 15, 2014: Keryx Biopharmaceuticals Announces Results From Ferric Citrate Phase 3 Long-Term Safety Extension Study | 65 | 1 |
| Oct 01, 2014: Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Ferric Citrate Covering Orally Administrable Forms | 66 | 1 |
| Apr 09, 2014: Keryx Biopharmaceuticals Announces Zerenex Phase 2 Results in Non-Dialysis Dependent Chronic Kidney Disease Selected as a Late Breaking Oral Presentation at the Upcoming National Kidney Foundation 2014 Spring Clinical Meeting | 67 | 1 |
| Apr 02, 2014: Keryx Biopharmaceuticals Announces EMA Validation of Marketing Authorization Application for Zerenex | 67 | 1 |
| Mar 10, 2014: Keryx Biopharmaceuticals Announces Submission of a Marketing Authorization Application for Zerenex to the European Medicines Agency | 68 | 1 |
| Jan 17, 2014: Keryx Biopharmaceuticals Announces Marketing Approval of Ferric Citrate in Japan | 68 | 1 |
| Oct 21, 2013: Keryx Biopharmaceuticals Announces PDUFA Goal Date for Zerenex New Drug Application | 69 | 1 |
| Oct 17, 2013: Keryx Biopharmaceuticals' Zerenex (Ferric Citrate Coordination Complex) Data Selected for Oral and Poster Presentations at the American Society of Nephrology's Kidney Week 2013 | 69 | 1 |
| Oct 08, 2013: Keryx Biopharmaceuticals Announces FDA Acceptance for Filing of Zerenex New Drug Application | 70 | 2 |
| Appendix | 72 | 2 |
| Methodology | 72 | 1 |
| Coverage | 72 | 1 |
| Secondary Research | 72 | 1 |
| Primary Research | 72 | 1 |
| Expert Panel Validation | 72 | 1 |
| Contact Us | 72 | 1 |
| Disclaimer | 73 | 1 |